Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). A randomised, open-label, proof of concept, Phase 2 study
Latest Information Update: 15 May 2023
Price :
$35 *
At a glance
- Drugs Alisporivir (Primary) ; Alisporivir (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Proof of concept; Therapeutic Use
- Acronyms CYCLOVID
- 09 May 2023 Status changed from recruiting to completed.
- 18 Jan 2021 According to a Debiopharm media release, the first patient has been dosed in this study.
- 18 Jan 2021 Status changed from not yet recruiting to recruiting, according to a Debiopharm media release.